FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Thomsen Jillian B.						2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]								neck all appli	cable)	ting Person(s) to Issuer 10% Owner Other (specify		/ner	
(Last) C/O NEI	(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS				3. Date of Earliest Transaction (Month/Day/Year) 12/15/2015								\exists	X Officer (give title Other (specify below) SVP & Chief Accounting Officer				·	
455 MISSION BAY BOULEVARD SOUTH																			
(Street) SAN FRANCISCO CA		94158		4. If	Line) X Form fil							Joint/Group Filing (Check Applicable led by One Reporting Person led by More than One Reporting							
(City)	(S	tate)	(Zip)																
		Tab	le I - Non-	Deriva	tive	Sec	curities	s Ac	quired,	Dis	posed o	f, or Be	neficia	ly Owned	l				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ar) E	A. Deeme execution f any Month/Da	Date	Code (I	Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3, 4		Benefici	es Formally (D) (Following (I) (I		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D) Pri		Transaci (Instr. 3	tion(s)			(111301.4)			
		-	Table II - D (e						uired, D s, option					Owned	,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	′ Co	Transactio				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode '	V	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit	(1)	12/15/2015		I	A		18,750		(2)	1	2/14/2023	Common Stock	18,750	\$0.00	18,750		D		
Stock	\$15.55	12/15/2015		A	A		22,500		(3)	1	2/14/2023	Common	22,500	\$0.00	22,500		D		

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.
- $2.\ This\ restricted\ stock\ unit\ vests\ over\ 3\ years\ in\ equal\ quarterly\ installments.$
- 3. This stock option vests in equal monthly installments over the 4-year period following the grant date.

Remarks:

Gil M. Labrucherie, Attorney-

12/17/2015

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.